

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

RECEIVED

FEB 28 2001

File Information

In re Application of

Platz

Application Number	Filed
08/246,034	5/18/94
Group Art Unit	Examiner

Paper No. #13

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

- (A) referred to in United States Patent Number 6,123,936, column _____,
- (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____,
- (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or
- (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Violetta Bonduke02/28/01

Date

Signature

Violatta Bonduke

Typed or printed name

FOR PTO USE ONLY

Approved by: JL

(Initials)

Unit: EPL

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



US006123936A

#B

United States Patent [19]

Platz et al.

[11] Patent Number: **6,123,936**
[45] Date of Patent: **Sep. 26, 2000**

[54] **METHODS AND COMPOSITIONS FOR THE DRY POWDER FORMULATION OF INTERFERONS**

[75] Inventors: Robert M. Platz, Half Moon Bay, Calif.; Shigenobu Kimura, Hyogo; Yu-ichiro Satoh, Sapporo, both of Japan; Linda C. Foster, Mountain View, Calif.

[73] Assignee: Inhale Therapeutics Systems, Inc., San Carlos, Calif.

[21] Appl. No.: 09/444,116

[22] Filed: Nov. 22, 1999

Related U.S. Application Data

[63] Continuation of application No. 08/737,724, filed as application No. PCT/US95/06008, May 15, 1995, which is a continuation-in-part of application No. 08/246,034, May 18, 1994, abandoned.

[51] Int. Cl.⁷ A61K 38/21; C07K 1/36

[52] U.S. Cl. 424/85.6; 530/351; 514/2; 435/70.1; 424/43; 424/46; 424/489; 424/491

[58] Field of Search 424/85.6, 85.4, 424/43, 46, 489, 491; 530/351, 363; 514/2, 21; 435/70.1; 128/200.14, 200.33

[56] References Cited

U.S. PATENT DOCUMENTS

5,049,389 9/1991 Radhakrishnan 424/450

FOREIGN PATENT DOCUMENTS

WO91/16038 10/1991 WIPO

WO93/00951 1/1993 WIPO

Primary Examiner—David Guzo

Assistant Examiner—Jon Shuman

Attorney, Agent, or Firm—Susan T. Evans; Felissa H. Cagan; Stephen L. Burst

[57] ABSTRACT

According to the present invention, methods and compositions are provided for spray-dried, interferon-based dry powder compositions, particularly interferon-beta. The compositions are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN.

22 Claims, No Drawings